To evaluate the therapeutic efficacy of combining agonistic anti-CD40 monoclonal antibody (anti-CD40 mAb) therapy with sunitinib treatment, we analyzed the response to combination therapy or monotherapy in two different murine subcutaneous tumor models, B16.F10 melanoma and T241 fibrosarcoma. The gene discussed is CD40; the disease is neoplasm.